149 related articles for article (PubMed ID: 11304785)
1. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Dowlati A; Hoppel CL; Ingalls ST; Majka S; Li X; Sedransk N; Spiro T; Gerson SL; Ivy P; Remick SC
J Clin Oncol; 2001 Apr; 19(8):2309-18. PubMed ID: 11304785
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
Merchant J; Tutsch K; Dresen A; Arzoomanian R; Alberti D; Feierabend C; Binger K; Marnoccha R; Thomas J; Cleary J; Wilding G
Clin Cancer Res; 2002 Jul; 8(7):2193-201. PubMed ID: 12114420
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study.
Langevin AM; Weitman SD; Kuhn JG; Weintraub ST; Baruchel S; Furman W; Bernstein M; Blaney S; Vietti T;
J Pediatr Hematol Oncol; 2003 Jul; 25(7):526-33. PubMed ID: 12847318
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Ricart AD; Hammond LA; Kuhn JG; Takimoto CH; Goetz A; Forouzesh B; Forero L; Ochoa-Bayona JL; Berg K; Tolcher AW; Rowinsky EK
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8728-36. PubMed ID: 16361560
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Langevin AM; Bernstein M; Kuhn JG; Blaney SM; Ivy P; Sun J; Chen Z; Adamson PC;
Pediatr Blood Cancer; 2008 Mar; 50(3):577-80. PubMed ID: 17610262
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
15. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
Dowlati A; Posey J; Ramanathan RK; Rath L; Fu P; Chak A; Krishnamurthi S; Brell J; Ingalls S; Hoppel CL; Ivy P; Remick SC
Cancer Chemother Pharmacol; 2009 Dec; 65(1):73-8. PubMed ID: 19399502
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
Goh BC; Ratain MJ; Bertucci D; Smith R; Mani S; Vogelzang NJ; Schilsky RL; Hutchison M; Smith M; Averbuch S; Douglass E
J Clin Oncol; 2001 Mar; 19(5):1476-84. PubMed ID: 11230494
[TBL] [Abstract][Full Text] [Related]
18. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
